The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

Distinguished International Competition for Bicycle Design Excellence Extends Late Entry Period ... Winners receive substantial benefits including the A' Design Award Winner Logo license, trophy, and ...

Adagene (ADAG – Research Report) received a Hold rating and price target from Morgan Stanley analyst Maxwell Skor today. The company’s shares ...

Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Fraser Murray, PhD, CEO, Pheno Therapeutics. Image Credit: Pheno Therapeutics A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to ...

Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company currently valued at $1.05 billion, is garnering attention from analysts for its innovative Bicycle platform technology ...

For the first time in almost 20 years, Walmart has a new logo. The international retailer describes it as a “a comprehensive brand refresh,” but the online world hasn’t been quite so kind to ...

Needham & Company LLC reiterated their buy rating on shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) in a research report released on Monday,Benzinga reports. They currently have a $ ...

These consortia vary in their scope, funding, and structure from government-funded models such as the National Cancer Institute Experimental Therapeutics Clinical ... (Inst), Sotio (Inst), Adaptimmune ...